Press release
Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies-Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ)-each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.Peraso Inc. (NASDAQ: PRSO) , a leader in millimeter wave (mmWave) technology, is targeting and advancing into the military wireless space-long dominated by legacy defense firms. Leveraging its patented 60GHz mmWave solutions, Peraso aims to deliver secure, high-speed communications across UAVs, radar systems, and battlefield networks.
The company holds key IP, including patents addressing interference management and beamforming antenna systems, giving it a tactical edge in next-gen defense communications. As global defense systems shift to next-gen wireless, demand for cost-effective, license-free mmWave connectivity is surging-positioning Peraso as a frontrunner ahead of larger, slower-moving competitors.
"Peraso's mmWave platform offers a strong alternative to traditional RF systems," said an industry analyst. CEO Ron Glibbery recently discussed the company's strategy on The Street Reports Podcast [https://thestreetreports.com/peraso-incs-ceo-ron-glibbery-discusses-the-future-of-60-ghz-mmwave-5g-ai-driven-connectivity-and-military-applications-on-the-street-podcast-listen-now/] , listen now.
With growing defense budgets and emphasis on unlicensed, high-throughput tech, Peraso is building long-term value in a rapidly evolving market-emerging as a high-potential wireless stock aligned with modern battlefield needs.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has signed a global licensing deal with Novo Nordisk for its oral obesity drug candidate LX9851 , potentially worth up to $1 billion, including $75 million in upfront and near-term milestones. LX9851, which targets the ACSL5 enzyme, has shown strong preclinical results, especially when paired with semaglutide. Novo Nordisk will handle development and commercialization, while Lexicon is eligible for tiered royalties on sales.
Portage Biotech (NASDAQ: PRTG) reported breakthrough preclinical results for PORT-7 , showing over 90% tumor reduction in mesothelioma models when combined with an anti-PD-1 antibody. Presented at the 2025 ELCC in Paris, the data marks the first evidence of selective A2B inhibition efficacy in this cancer type. Portage plans to launch a first-in-human trial and is also advancing PORT-6 , a selective A2A inhibitor, with plans to combine both agents in the ADPORT-601 trial for enhanced immunotherapy impact.
TransCode Therapeutics (NASDAQ: RNAZ) has dosed the first patient in Cohort 4 of its Phase 1 trial for TTX-MC138 , an RNA therapy targeting metastatic cancer via microRNA-10b inhibition. Ten patients have been treated so far with no major safety issues. The latest dose is 50% higher than in the previous cohort, with more patients being evaluated for enrollment.
From Peraso's patent-backed 60GHz mmWave wireless tech gaining traction in military communications, to Lexicon's $1B obesity licensing deal with Novo Nordisk, Portage's novel adenosine pathway immunotherapy in mesothelioma, and TransCode's advancement of RNA cancer therapeutics with no safety red flags-these emerging players are reshaping their sectors with disruptive potential. As investor interest shifts toward science-backed innovation and defense-grade infrastructure, PRSO, LXRX, PRTG, and RNAZ are fast becoming tickers to watch in 2025's next-generation growth landscape.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=emerging-tech-quartetprso-lxrx-prtg-rnaz-drive-breakthroughs-across-defense-obesity-oncology-and-rna-therapeutics]
Country: United States
Website: http://www.thestreetreports.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics here
News-ID: 3945841 • Views: …
More Releases from ABNewswire

Worldle Goes Gaeilge: Global Hit Game Adds Irish Language, Announced at NEXUS Ir …
DUBLIN, Ireland - Oct 2, 2025 - Today at the NEXUS Irish Games Industry Conference, Games publisher Teuteuf Games announced a significant update for its viral geography game, Worldle: the addition of the Irish language (Gaeilge). The update, which goes live today, makes Irish the 12th language supported in the daily puzzle game that has captivated millions across the globe.
Launched three years ago, Worldle has become a global phenomenon. The…

Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility.
Built for Drivers Who Want More Than Just Rides
Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on…

UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we…

3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering …
Imagine being able to capture every nook and cranny of an object down to the most intricate detail. Sounds magical, right? That's the power of 3D scanning services [https://3d-engineering.net/engineering-services/3d-laser-scanning-services/] in today's engineering projects. Across industries, from automotive and construction to aerospace and healthcare, 3D scanning is transforming how things are measured, mapped, and made. Whether you're designing a new building or manufacturing precision components, 3D scanning takes you from the…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…